# MuseCell dossier · specimen s_07f98c80cd

Run `run_9afbd903a2d2` · blinded · 2026-10-31 19:34 UTC · models: scientist muse-spark-1.3, microscopist muse-spark-1.3, reviewer muse-wonder-1.0, segmentation classical (scikit-image), provider meta, atlas ResNet50 (ImageNet) + TVN, agent v5

**Question.** Which mechanism-of-action class explains this compound's phenotype in MCF-7 cells?

## Experiments (4 of 4 wells)

| Evidence | Dose (µM) | Replicate | Cells | Strongest changes vs DMSO |
|---|---|---|---|---|
| e2 | 10 | 1 | 112 | tub_glcm_contrast z=+185.2; act_std z=+179.3; act_glcm_contrast z=+138.0 |
| e3 | 0.3 | 1 | 346 | act_std z=+66.9; act_glcm_contrast z=+50.3; tub_glcm_contrast z=+38.5 |
| e7 | 1 | 1 | 201 | act_std z=+139.0; tub_glcm_contrast z=+138.7; act_glcm_contrast z=+104.4 |
| e8 | 0.1 | 1 | 190 | nuc_solidity z=-78.3; act_glcm_contrast z=+30.2; act_std z=+25.9 |

## Steps

1. `list_available_experiments` — Need dose list and budget to plan discriminating wells.
2. `acquire_well` — High dose should show maximal phenotype and cell loss if cytotoxic.
3. `acquire_well` — Mid dose to capture onset of phenotype before full toxicity.
4. `compare_to_reference_atlas` — Nearest reference treatments will separate antimitotic classes.
5. `describe_phenotype` — Visual check for mitotic figures vs multinucleation and cytoskeleton.
6. `update_hypotheses` — NSC says actin but similarity low and microscopist favors antimitotic; keeping both.
7. `acquire_well` — 1 uM between strong 0.3 and 10 uM tests reproducibility and NSC stability.
8. `acquire_well` — 0.1 uM just below onset at 0.3 uM defines dose threshold for mitotic arrest.
9. `compare_to_reference_atlas` — Refresh NSC vote over all four wells for final protocol call.
10. `dose_response` — Mitotic fraction dose trend distinguishes antimitotic classes.
11. `dose_response` — Tubulin intensity trend separates stabilizers from destabilizers.
12. `update_hypotheses` — Four wells show dose mitotic arrest; atlas split with low similarity, microscopist antimitotic.
13. `submit_conclusion` — NSC prior is leading class though split and low similarity; dose mitotic arrest retained.
14. `describe_phenotype` — Requested dose 5 rep 1 already acquired as w_e741eff746; visual re-analysis since budget spent.
15. `dose_response` — Multinucleation trend helps separate actin/cytokinesis failure from pure mitotic arrest.
16. `dose_response` — Actin intensity trend tests actin-loss expectation versus rounding-driven increase.
17. `dose_response` — Cell shrinkage trend tests rounding arrest versus spreading phenotypes.
18. `dose_response` — Large-nucleus trend separates endoreduplication from monopolar arrest.
19. `update_hypotheses` — Requested dose 5 re-examined via free tools; budget spent so no new well; antimitotic signal consistent.
20. `submit_conclusion` — Requested dose 5 rep1 already acquired; budget spent, no new well. NSC split 2/4 low sim; microscopist plus dose arrest favor Eg5 but stabilizer monopolar distinction remains uncertain.
21. `lookup_compound` — Protocol step after the review: identify the unblinded specimen in PubChem and ChEMBL.
22. `search_literature` — Need papers on true MoA of unblinded compound for reflection.

## Hypothesis history

- after step 6: Actin disruptors 0.35, Eg5 inhibitors 0.30, Microtubule destabilizers 0.20, Microtubule stabilizers 0.15
- after step 12: Eg5 inhibitors 0.45, Actin disruptors 0.25, Microtubule destabilizers 0.15, Microtubule stabilizers 0.15
- after step 19: Eg5 inhibitors 0.52, Microtubule stabilizers 0.26, Actin disruptors 0.12, Microtubule destabilizers 0.10

## Conclusion 1

**Actin disruptors** (stated probability 0.42); key evidence e9, e2, e7, e10, e5.

Why: NSC prior is leading class though split and low similarity; dose mitotic arrest retained.

Next experiment if this were a real lab: Stain for phospho-histone H3 plus pericentrin/alpha-tubulin to test monopolar vs bipolar arrest and actin phalloidin fiber integrity, comparing reference of leading class versus reference Eg5 and microtubule classes across 0.1-10 uM.

## Conclusion 2

**Eg5 inhibitors** (stated probability 0.52); key evidence e9, e5, e14, e10, e11.

Why: Requested dose 5 rep1 already acquired; budget spent, no new well. NSC split 2/4 low sim; microscopist plus dose arrest favor Eg5 but stabilizer monopolar distinction remains uncertain.

Next experiment if this were a real lab: Phospho-histone H3 plus pericentrin/tubulin spindle imaging across 0.1-10 uM to test monopolar versus bipolar arrest and actin fiber integrity versus reference Eg5 and stabilizer class controls.

## PI review

Verdict: request experiment.

Clean profile schema: short labels, class means, and percentages. Eg5 fragments 12/20 = 60% and stabilizers 5/21 = 24% shown. Directly enables the stabilizer exclusion argument.

Requested: ACQUIRE dose index 5 rep 1 (no more wells needed after)

## Unblinding

Compound: **cytochalasin D** (PubChem CID [5458428](https://pubchem.ncbi.nlm.nih.gov/compound/5458428))

Identity check: name only (the BBBC021 structure is not in PubChem)

ChEMBL mechanisms: no curated mechanism in ChEMBL

## Verdict (computed by code)

Correct: the call was **Actin disruptors**, BBBC021 annotates **Actin disruptors**.

The final call is the nearest-neighbour vote over the 4 wells the agent chose (2/4). The Scientist's own call was **Eg5 inhibitors** (dissents; wrong).

## Reflection

Early evidence was right: 10 uM well w_bdc02a8567 with act_std z=+179.3 and act_glcm_contrast z=+138.0 and 0.3 uM well with act_std z=+66.9 gave NSC 2/2 Actin disruptors, and protocol majority 2/4 remained Actin disruptors. That direct actin texture mass reflects the true cytochalasin D mechanism of capping filaments to block polymerization (PMID 3023337) and capping/severing observed structurally (PMID 40658853).

I overturned that correct lead because two describe_phenotype calls listed only Microtubule stabilizers/destabilizers/Eg5 inhibitors and never actin, k-neighbours were 5/10 Eg5 inhibitors, and dose_response showed frac_mitotic_like rho=+1.00, tub_mean rho=+1.00 and cell_area rho=-1.00. I misread rounding/shrinkage and high tub_glcm_contrast z=+185.2 as monopolar mitotic arrest rather than contracted actin-collapsed cells scoring mitotic-like, and misread act_mean rho=+0.80 and falling multinucleate proxy as against cytokinesis failure.

Acquisition choice cemented the error: with only 4 wells spent on 10, 0.3, 1 and 0.1 uM, the 1 uM well called Eg5 inhibitors and 0.1 uM called Protein synthesis at similarity ~0.599, diluting the vote and lowering confidence. I should have weighted extreme act_std z>100 and summed similarity 1.225 for actin over generic mitotic proxies and required a phalloidin fiber check, consistent with actin-cofilin inhibition by cytochalasin D (PMID 22728040), before switching final call to Eg5 inhibitors p=0.52.

What was right:
- High-dose act_std z=+179.3 and act_glcm_contrast z=+138.0 in e2 plus mid-dose act_std z=+66.9 in e3 flagged strong actin cytoskeleton disruption
- Early NSC vote 2/2 Actin disruptors in e4 correctly captured the leading class
- First submit_conclusion Actin disruptors p=0.42 matched unblinded protocol majority 2/4 with summed similarity 1.225

What was wrong or missed:
- Over-weighted describe_phenotype e5 and e14 which proposed only microtubule/Eg5 candidates and omitted actin, despite low-density rounded cells also seen in actin collapse
- Interpreted dose_response frac_mitotic_like rho=+1.00 in e10 and tub_mean rho=+1.00 in e11 as Eg5-specific arrest rather than actin-contraction artifact raising texture contrast
- Interpreted cell_area rho=-1.00 in e17 and lower density as Eg5 rounding instead of actin-disruptor shrinkage/detachment
- Let k-neighbour Eg5 5/10 in e4/e9 outweigh NSC leading vote and low-similarity warning, leading to final wrong Eg5 inhibitors p=0.52 in e20

Proposed next experiment: Phalloidin actin fiber imaging plus phospho-histone H3 and pericentrin/alpha-tubulin spindle imaging across 0.1-10 uM with actin-disruptor versus Eg5-inhibitor controls to test fiber loss/collapse versus true monopolar arrest.

## Citations

Citations verified: 3/3

- PMID [3023337](https://pubmed.ncbi.nlm.nih.gov/3023337/): Actin polymerization. The mechanism of action of cytochalasin D. *J Biol Chem* (1986) — Cytochalasin D blocks actin polymerization by capping filament ends.
- PMID [40658853](https://pubmed.ncbi.nlm.nih.gov/40658853/): Microscopic and structural observations of actin filament capping and severing by cytochalasin D. *Proc Natl Acad Sci U S A* (2025) — Structural and microscopic work shows cytochalasin D caps and severs actin filaments.
- PMID [22728040](https://pubmed.ncbi.nlm.nih.gov/22728040/): Cytochalasin D acts as an inhibitor of the actin-cofilin interaction. *Biochem Biophys Res Commun* (2012) — Cytochalasin D acts as an inhibitor of the actin-cofilin interaction.

Cost: $0.4974 over 17 model calls; 14 Scientist turns.

*Research tool for cell-biology screening data. Not for clinical use.*
